Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Etoposide
Drug ID BADD_D00854
Description A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Indications and Usage For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
Marketing Status Prescription; Discontinued
ATC Code L01CB01
DrugBank ID DB00773
KEGG ID D00125
MeSH ID D005047
PubChem ID 36462
TTD Drug ID D0B7EB
NDC Product Code 63323-104-05; 63323-104-25; 63323-104-50; 0703-5653-01; 0703-5656-01; 0703-5657-01; 0703-5656-91; 0703-5657-91; 68001-265-22; 68001-265-25; 68001-265-23; 68001-265-26; 68001-265-24; 68001-265-27; 16729-114-31; 16729-114-32; 16729-114-08; 16729-114-11; 16729-262-31; 16729-262-32; 0378-3266-94
Brand Etoposide [Fresenius Kabi USA, LLC]; Toposar [Teva Parenteral Medicines, Inc.]; Toposar [Teva Parenteral Medicines, Inc.]; Etoposide [BluePoint Laboratories]; Etoposide [Accord Healthcare Inc.]; Etoposide [Accord Healthcare Inc.]; Etoposide [Mylan Pharmaceuticals Inc.]
Synonym Etoposide | Eposide | Demethyl Epipodophyllotoxin Ethylidine Glucoside | Eto-GRY | Eto GRY | Etoposide, (5a alpha,9 alpha)-Isomer | Etoposide, (5S)-Isomer | Etoposide, alpha-D-Glucopyranosyl Isomer | Etoposide, alpha D Glucopyranosyl Isomer | alpha-D-Glucopyranosyl Isomer Etoposide | Etoposido Ferrer Farma | Exitop | Lastet | NSC-141540 | NSC 141540 | NSC141540 | Onkoposid | Riboposid | Toposar | Etoposide Teva | Teva, Etoposide | Vepesid | VP 16-213 | VP 16 213 | VP 16213 | VP-16 | VP 16 | VP16 | Vépéside-Sandoz | Vépéside Sandoz | Celltop | Etopos | Etomedac | Eposin | Etoposide, (5a alpha)-Isomer | Etoposide Pierre Fabre
Chemical Information
Molecular Formula C29H32O13
CAS Registry Number 33419-42-0
SMILES CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC) O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ApoptosisDNA topoisomerase 2-alphaP11388T1704810454518; 9415703; 9488042; 11389075
Cell deathB-cell receptor-associated protein 31P51572Not AvailableNot Available
Cell deathCaspase-8Q14790T15700Not Available
Cell deathDNA topoisomerase 2-alphaP11388T1704810454518; 9415703; 9488042; 11389075
Cell deathCaspase-3P42574T57943Not Available
Cell deathMitogen-activated protein kinase 9P49186Not AvailableNot Available
Cell deathAbscisic acid-inducible protein kinaseQ02066Not AvailableNot Available
Cell deathHistone-binding protein RBBP7Q16576Not AvailableNot Available
Cell deathMitogen-activated protein kinase 1P28482T58970Not Available
Cell deathMitogen-activated protein kinase 8P45983T40097Not Available
Cytogenetic abnormalityRetinoblastoma tumor suppressorQ5J3Q9Not Available11156401; 11094065; 10811120
Cytogenetic abnormalityHypoxanthine-guanine phosphoribosyltransferaseP00492Not Available7664276; 2328496; 1681541; 11788894; 7969039; 8395979; 8467505
Drug ineffectiveProtein E7P03129T8507211156401; 11094065; 10811120
Gene mutationApoptosis regulator Bcl-2P10415T313097664276; 2328496; 1681541; 11788894; 7969039; 8395979
LeukaemiasHistone-lysine N-methyltransferase 2BQ9UMN6Not Available8078192; 9436917; 12537982; 11520560; 7948964; 7948964; 9226152; 11911106
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Acute leukaemia16.01.02.001; 01.10.02.001--Not Available
Acute lymphocytic leukaemia16.01.01.001; 01.10.01.001--Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.001--Not Available
Acute promyelocytic leukaemia16.01.05.003; 01.10.05.003--Not Available
Acute respiratory distress syndrome22.01.03.001--
Agranulocytosis01.02.03.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Aplasia08.03.04.003; 03.02.01.002--Not Available
Apnoea22.02.01.001--
Arthralgia15.01.02.001--
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Blindness cortical06.02.02.004; 17.17.01.017--Not Available
Blood albumin decreased13.09.01.001--Not Available
Blood creatinine increased13.13.01.004--
Blood pressure decreased13.14.03.002--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood uric acid increased13.02.04.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 10 Pages